Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRX NASDAQ:KURA NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$0.38$0.27$0.00▼$3.87$4.94M0.833,794 shsN/AKURAKura Oncology$9.42+1.1%$8.79$5.45▼$12.49$827.27M0.321.21 million shs889,128 shsSNDXSyndax Pharmaceuticals$21.49+4.6%$23.06$8.58▼$25.59$1.82B0.411.67 million shs2.18 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%-20.00%+11.40%+52.00%-80.00%KURAKura Oncology-2.51%+5.55%+5.67%+19.03%+65.25%SNDXSyndax Pharmaceuticals-0.53%-4.15%-16.64%-2.24%+105.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$0.38$0.27$0.00▼$3.87$4.94M0.833,794 shsN/AKURAKura Oncology$9.42+1.1%$8.79$5.45▼$12.49$827.27M0.321.21 million shs889,128 shsSNDXSyndax Pharmaceuticals$21.49+4.6%$23.06$8.58▼$25.59$1.82B0.411.67 million shs2.18 million shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals0.00%-20.00%+11.40%+52.00%-80.00%KURAKura Oncology-2.51%+5.55%+5.67%+19.03%+65.25%SNDXSyndax Pharmaceuticals-0.53%-4.15%-16.64%-2.24%+105.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AKURAKura Oncology 2.69Moderate Buy$26.38179.99% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.6498.40% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, KURA, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/21/2026KURAKura Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026KURAKura Oncology Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$23.004/14/2026KURAKura Oncology Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$23.004/1/2026SNDXSyndax Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $34.003/31/2026SNDXSyndax Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $43.003/30/2026SNDXSyndax Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.00 ➝ $40.003/27/2026SNDXSyndax Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026KURAKura Oncology MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $25.003/13/2026KURAKura Oncology UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00 ➝ $15.003/9/2026SNDXSyndax Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $45.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.02$0.95 per share0.40N/A∞KURAKura Oncology$67.48M12.39N/AN/A$2.00 per share4.71SNDXSyndax Pharmaceuticals$217.17M8.77N/AN/A$0.47 per share45.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64M$1.180.32N/AN/AN/AN/AN/A5/11/2026 (Estimated)KURAKura Oncology-$278.67M-$3.18N/AN/AN/A-412.95%-102.59%-39.61%5/12/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%N/ALatest SNDX, KURA, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026KURAKura Oncology-$0.88N/AN/AN/A$25.97 millionN/A4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million3/5/2026Q4 2025KURAKura Oncology-$0.72-$0.92-$0.20-$0.92$34.71 million$17.34 million2/26/2026Q4 2025SNDXSyndax Pharmaceuticals-$0.64-$0.78-$0.14-$0.78$64.75 million$68.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AKURAKura Oncology0.066.066.05SNDXSyndax Pharmaceuticals8.265.474.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%KURAKura OncologyN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%KURAKura Oncology7.60%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataKURAKura Oncology13088.76 million82.02 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableSNDX, KURA, and EGRX HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 5 at 7:15 PM | seekingalpha.comBiotech Momentum Builds As Syndax Pharmaceuticals Draws Market AttentionMay 5 at 3:23 PM | kalkinemedia.comKBank of America Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)May 5 at 3:23 PM | theglobeandmail.comHC Wainwright Has Optimistic Outlook of SNDX Q2 EarningsMay 5 at 8:32 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst UpgradeMay 4, 2026 | marketbeat.comHC Wainwright Has Bullish Outlook for SNDX FY2030 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Has Optimistic Outlook of SNDX FY2030 EarningsMay 4, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 7.1% - Should You Sell?May 3, 2026 | americanbankingnews.comSyndax Slide Puts Nasdaq Index Biotech in FocusMay 2, 2026 | kalkinemedia.comKSyndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...May 2, 2026 | finance.yahoo.comSyndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?May 2, 2026 | finance.yahoo.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?May 1, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00May 1, 2026 | marketbeat.comSyndax: Q1 Earnings SnapshotApril 30, 2026 | stamfordadvocate.comSSyndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comSyndax Pharmaceuticals Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings ResultsApril 30, 2026 | marketbeat.comSyndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue EstimatesApril 30, 2026 | zacks.comSyndax Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comNuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings GrowthApril 27, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, KURA, and EGRX Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$0.38 0.00 (0.00%) As of 05/7/2026Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Kura Oncology NASDAQ:KURA$9.42 +0.10 (+1.07%) Closing price 04:00 PM EasternExtended Trading$9.41 -0.01 (-0.05%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Syndax Pharmaceuticals NASDAQ:SNDX$21.49 +0.95 (+4.63%) As of 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
